![Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ... Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...](https://www.thelancet.com/cms/attachment/e13b1a04-0d02-4b38-95c8-7c067ac1e621/gr1.jpg)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
![Eurofase 13733-018 MYA 3-Light Track, Satin Nickel - Directional Spotlight Ceiling Fixtures - Amazon.com Eurofase 13733-018 MYA 3-Light Track, Satin Nickel - Directional Spotlight Ceiling Fixtures - Amazon.com](https://m.media-amazon.com/images/I/31Ge2CSDbkL._AC_UF894,1000_QL80_.jpg)